Dana-Farber Cancer Institute · 3 weeks ago
Antibody Discovery & Engineering Scientist I/II – CAR-T Cell & Antibody Therapies
Boston, MA
Full-time
Onsite
Mid, Senior Level
$80K/yr - $96K/yr
7+ years expDana-Farber Cancer Institute is seeking an experienced PhD-level scientist to join their antibody discovery and antibody-based therapeutics development team. The role focuses on developing strategies for antibody selection and engineering, collaborating with multidisciplinary teams to advance next-generation immunotherapy candidates.
CommunitiesHealth CareHealth DiagnosticsHospitalNon ProfitOncology
Responsibilities
This “leading from the bench” role provides scientific and technical expertise within multidisciplinary project teams focused on the development of antibody-based immunotherapies
Develop antibody selection strategies to identify novel, fully human binders from a custom library using phage- and yeast-display
Design experiments to characterize (e.g. binding, function, biophysical characterization & developability) antibody-based binders used to generate antibody-based drug modalities including CARs, multispecific T cell engagers, etc
Design, produce and optimize the expression and in vitro function of logic-gated and/or multispecific CARs and antibodies
Evaluate novel approaches to antibody and CAR-T screening including the construction of candidate libraries and high-throughput pooled or arrayed screening approaches that leverage the use of automation
Design and execute workflows for producing and functionally screening antibody-based biologics and CAR-T candidates to identify leads for clinical translation
Collaborate with team members across groups and mentor junior lab members to implement best practices for the operation and maintenance of immunotherapy production, screening and engineering platforms
Co-author technical reports and manuscripts for publication or presentation at internal and external meetings
Operate and maintain laboratory instruments
Qualification
Required
PhD scientist with experience in antibody screening, engineering and/or CAR-T engineering
A candidate with a M.S. degree and substantial experience (>7 years) may also be considered for this role
Strong track record, hands-on experience, and in-depth knowledge in at least two of the following domain areas: antibody discovery (phage and yeast display strategies, affinity maturation approaches, etc.); antibody expression and characterization technologies including but not limited to purity and mispairing (SEC), aggregation/stability (DLS) as well as affinity characterization (SPR); generative AI tools for protein or antibody design (exposure and familiarity to Alphafold3, RoseTTAFold, ProteinMPNN, MOE and/or other bioinformatic tools for protein modeling and de novo protein design)
Previous hands-on experience engineering antibody and/or CAR-T candidates and executing key functional assays for candidate screening (assessments of cytotoxicity via plate-based or imaging-based assays, tonic signaling, developability, etc.)
Exceptionally self-motivated and capable of taking scientific initiatives
Excellent communication (written and verbal) and troubleshooting skills as well as the ability to work with a wide variety of collaborators
Outstanding planning, organizational, and multi-tasking skills
Must consider attention to detail a strength
Ability to work within a fast-paced team environment
Preferred
Industry research experience is a plus
Company
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
1001-5000 employees
H1B Sponsorship
Dana-Farber Cancer Institute has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (191)
2024 (145)
2023 (155)
2022 (139)
2021 (105)
2020 (113)
Funding
Current Stage
Late StageTotal Funding
$88.08MKey Investors
Elaine and Eduardo Saverin FoundationThe DeGregorio Family FoundationLlama
2025-11-24Grant· $20M
2025-05-06Grant· $1M
2024-09-24Grant· $0.5M
Leadership Team
Edward Benz
CEO
Recent News
2026-01-25
GlobeNewswire
2026-01-22
Company data provided by crunchbase